Amarin appeals ‘skinny label’ loss
Generic heart drug was found to not infringe Amarin’s blockbuster treatment earlier this year | Health insurer Health Net tied to case after allegedly promoting use of the generic.
Pharma owners warned of Brexit effect on TMs
Large market for parallel or ‘grey’ imports of pharmaceuticals due to pricing differences in various countries | Govt consultation respondents unhappy with ‘lack of EU reciprocity’| Mewburn Ellis.
MSD makes $1.4bn bid on biopharma company
Move could garner ‘milestone’ treatment for one of MSD’s portfolios | Activity comes after a Spanish watchdog fined the pharma firm $39 million.
California firm entices quartet of litigators from rival
Life sciences practice boosted by four-partner ‘powerhouse’ team | Attorneys have all achieved notable trial outcomes for pharma companies.
Teva secures victory in iron overload treatment dispute
Judge Hacon rules that a skilled team “would have thought it obvious” to reformulate drug into a tablet | Teva DFX patents also found not to infringe, falling outside the claims on both a normal construction and under the doctrine of equivalents.
Big pharma steps up access, but uneven progress made: report
Licensing of COVID-19 treatments has shifted to include other medicines and treatment areas | World’s largest pharma companies still “consistently overlook the poorest countries” | Report offers strategy to improve access.
Patent firms unveil joint UPC ‘powerhouse’
Firms aim to form a UPC litigation alliance | New court has significant implications for life sciences | UPC faces calls for delay over concerns regarding its case management system.
FTC wades into escalating ‘Orange Book’ clash
Jazz accused a rival of infringement | Avadel filed a counterclaim seeking to delist the patent from the Orange Book.
English appeals court rejects jurisdiction challenge over cannabis sativa collab
Case concerns epilepsy drug patent and medical cannabis R&D collaboration | Dispute between Japanese and Irish pharma firms will be heard in London due to arbitration carve-out clause.
SCOTUS rejects BMS vs Gilead patent clash
Dispute over patent relating to a CAR-T cell therapy shunned by top court | Backing from Amgen, GSK and St. Jude's Children's Research Hospital over “exceedingly narrow” patent protection fails to convince Justices.
